comprehensive -WSS

comprehensive

author：focus 2025-10-01 17:30:02 - browse：4221

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Fertility clinic egg and embryo storage is a disaster

knowledge

leisure time

WSS

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Health and fitness trackers are measuring the wrong things

Fertility clinic egg and embryo storage is a disaster

Heart disease and mental health: A look at cardiac psychology

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Heart disease and mental health: A look at cardiac psychology

focus

comprehensive

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Three issues to watch in global health in 2024

At least 13 dead in Texas as scorching temps continue

The SUPPORT Act is critical to fighting the opioid crisis

Medical leaders decry Supreme Court decision on affirmative action

STAT reporters are Pulitzer Prize finalists for investigative reporting

Activists slam private health insurers over coverage restrictions

The nurse manager staffing crisis is hurting patients

Anesthesiologist group: stop taking Ozempic before surgery

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

hotspot

ALS treatment from Biogen, Ionis fails in study

What a koala virus tells us about the human genome

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

What a koala virus tells us about the human genome

Designating disabled people as health disparity population is crucial

DeSantis can now import cheaper drugs. But will Biden get credit?

knowledge

leisure time

leisure time

hotspot